source · text/markdown
source_15d3545409044bd9
sha256 ce0b9d9afa77abca8fed960b2ecaf93380bc8160eb9cfbb17e7ea58d2a038fbc
by researka:v2 · 2026-06-24 19:37:59.504620+04:00
# Adjacent Evidence Brief: Young plasma — full paper ## Abstract Evidence-honesty note: 13/17 retained sources are coded as null or no extracted directional signal; this corpus is non-supportive for clinical efficacy claims and hypothesis-generating only. Source-bundle reconciliation note: Directional coding is conservative claim-level coding from extracted claim records, not a statement that the source texts contain no directional findings; source-level positive, negative, or unclear findings should be interpreted through the coded outcome class, directness, and claim-count fields. The retained evidence has no direct interventional hard-endpoint evidence; indirect, review-level, adjacent, or mechanistic sources are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims. This paper synthesizes evidence on Young plasma across 17 accepted source papers and 474 high-confidence extracted claims. The evidence profile contains no sources classified primarily as direct interventional hard-endpoint evidence, 9 adjacent clinical sources, and 8 mechanistic or model-system sources, with 7 cross-study disagreements across the evidence base. Positive study-level signals are summarized in the mechanism and longevity outcome classes, null signals in the contextual adjacent evidence, mechanism, immune and inflammation outcome classes, and negative signals in no dominant outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect. The conclusion is that Young plasma remains a bounded geroscience case: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim. ## Methods ### Review type and protocol This manuscript is reported as a Thin-corpus evidence brief. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-young_plasma_parabiosis-v06-DAILY-2026-06-24T11-33-06Z-R2`. ### Information sources Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-06-24. ### Search strategy The following topic-anchored queries were executed against the information sources listed above: - `young plasma AND aging AND human` - `heterochronic parabiosis AND aging` - `young blood AND rejuvenation AND safety` - `plasma factors AND cognition AND aging` - `young plasma AND clinical trial` ### Eligibility criteria - Sources whose primary content addresses young plasma parabiosis. - Sources with extractable quantitative or qualitative findings. - Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable. - Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle). ### Selection of sources of evidence The synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 70 records in the receipt-candidate union, 27 were classified as source candidates and 17 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission. ### source admission funnel | Admission bucket | n | |---|---:| | Receipt candidate union | 70 | | Classified source candidates | 27 | | No extractable claims | 10 | | None-only claim binding | 4 | | Mixed partial-or-none claim-binding candidates | 23 | | Partial-only claim-binding candidates | 4 | | Strict high-confidence sources | 2 | | Admitted final sources | 17 | ### Exclusion reasons - No records were excluded at the gates instrumented for this run: the eligibility criteria above were applied during retrieval and claim-binding but produced no post-screening exclusions with recorded counts for this corpus. ### Data items The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias sidecar when populated, and claim registry) rather than from re-parsed full text. ### Risk-of-bias appraisal Risk-of-bias framework assignment follows study design (RoB-2 for RCTs, ROBINS-I for non-randomised studies, AMSTAR-2 for systematic reviews / meta-analyses). Public appraisal claims are limited to populated `risk_of_bias.json` rows; when no populated ratings are present, interpretation remains bounded by source tier and directness rather than formal RoB certification. ### Synthesis approach Evidence-tension synthesis: claims grouped by outcome class (contextual adjacent evidence, immune and inflammation, longevity, mechanism, safety and comorbidity, skeletal, fracture, and bone); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates. ### AI-use disclosure Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified. ### Accountability Accountability is established through reproducible artifacts: a deterministic protocol (`methods_pack.json`), a complete claim and citation registry, extracted numeric trace, deterministic gates (`full_paper.journal_surface.json`, `pre_submit_gate.json`, `artifact_consistency.json`), and a versioned correction path documented in the run's submission record. Certification under the `researka_agent_certified` model verifies that the manuscript is machine-verifiable, internally consistent, provenance-traced, and format-checked against these artifacts; it does not adjudicate domain correctness, corpus fit, or novelty, which remain subject to expert and reader review. ## Evidence Landscape ### Species and Study-Design Summary | Evidence group | Study-design signal | n | Example sources | Interpretation boundary | |---|---|---:|---|---| | Preclinical rodent n=8 | animal/preclinical experiment | 8 | Habibi 2024: Effect of Young Plasma Therapy on Cognition, Oxidative Stress, miRNA-134, BDNF, ; Zhao 2020: Young blood plasma reduces Alzheimer’s disease-like brain pathologies and amelio; Li 2022: Young plasma reverses anesthesia and surgery-induced cognitive impairment in age | Preclinical rows support mechanism only; they do not establish human efficacy. | | Other/unclear species n=6 | unclear or mixed design | 6 | Ceylani 2023: The rejuvenating influence of young plasma on aged intestine; Baba 2025: Therapeutic potential of young plasma in reversing age-related liver inflammatio; Yuan 2019: Young plasma ameliorates aging-related acute brain injury after intracerebral he | Unclear rows are retained only as bounded contextual evidence. | | Cell/in vitro n=1 | cell or ex vivo model | 1 | Chen 2024: Small extracellular vesicles from young plasma reverse age-related functional de | Cell-model rows are mechanistic context, not organism-level efficacy evidence. | | Human n=1 | clinical trial/intervention or safety cohort | 1 | Parker 2020: Safety of Plasma Infusions in Parkinson's Disease | Human rows bound clinical interpretation but do not prove broad geroprotection without hard-endpoint follow-up. | | Human n=1 | observational/donor or cohort evidence | 1 | Muraglia 2024: A simple cell proliferation assay and the inflammatory protein content show sign | Human observational rows are interpreted as association or feasibility evidence. | In animal/preclinical evidence, substantive evidence synthesis: The manifest includes 17 retained sources, 0 direct-source row(s), and directional coding across null=13, positive=3, unclear=1. Representative source-level signals are: Zhao 2020: outcome=Mechanism; direction=positive; directness=mechanistic; tier=C1; claims=48; Yuan 2019: outcome=Longevity; direction=positive; directness=indirect; tier=B2; claims=31; Chiavellini 2024: outcome=Mechanism; direction=positive; directness=mechanistic; tier=C1; claims=19; O 2026: outcome=Immune and Inflammation; direction=unclear; directness=review; tier=B1; claims=1; Chen 2024: outcome=Contextual Adjacent Evidence; direction=null; directness=indirect; tier=B2; claims=76; Habibi 2024: outcome=Mechanism; direction=null; directness=mechanistic; tier=C1; claims=51; Ceylani 2023: outcome=Contextual Adjacent Evidence; direction=null; directness=indirect; tier=B2; claims=36; Li 2022: outcome=Mechanism; direction=null; directness=mechanistic; tier=C1; claims=34. These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating. ## Key Findings In animal/preclinical evidence, key findings from source synthesis: First, the strongest positive or favorable signals are treated as narrow source-level signals, not broad clinical proof (Zhao 2020: outcome=Mechanism; direction=positive; directness=mechanistic; tier=C1; claims=48; Yuan 2019: outcome=Longevity; direction=positive; directness=indirect; tier=B2; claims=31; Chiavellini 2024: outcome=Mechanism; direction=positive; directness=mechanistic; tier=C1; claims=19). Second, negative, mixed, unclear, or no-directional-signal rows are given equal interpretive weight (O 2026: outcome=Immune and Inflammation; direction=unclear; directness=review; tier=B1; claims=1; Chen 2024: outcome=Contextual Adjacent Evidence; direction=null; directness=indirect; tier=B2; claims=76; Habibi 2024: outcome=Mechanism; direction=null; directness=mechanistic; tier=C1; claims=51). Third, the bounded conclusion follows from the balance of source direction, outcome class, evidence tier, and directness rather than from source count alone. ## Results | Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation | |---|---|---|---|---| | Mechanism | n=5; claims=177 | no extracted directional signal in 3/5 sources | 5 mechanistic | limited corpus depth in this outcome class | | Contextual Adjacent Evidence | n=4; claims=134 | no extracted directional signal in 4/4 sources | 4 indirect | limited corpus depth in this outcome class | | Immune and Inflammation | n=4; claims=85 | no extracted directional signal in 3/4 sources | 1 indirect; 2 mechanistic; 1 review | limited corpus depth in this outcome class | | Safety and Comorbidity | n=2; claims=44 | no extracted directional signal in 2/2 sources | 1 indirect; 1 mechanistic | limited corpus depth in this outcome class | | Longevity | n=1; claims=31 | positive signal in 1/1 sources | 1 indirect | single-source slice; hypothesis-generating | | Skeletal, Fracture, and Bone | n=1; claims=3 | no extracted directional signal in 1/1 sources | 1 indirect | single-source slice; hypothesis-generating | **Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim. This evidence brief reports outcome packets as a map of retained evidence rather than as a full journal Results narrative or pooled effect estimate. ### Mechanism Outcomes 5 included sources were assigned to this outcome class. Directional coding: null=3, positive=2. Directness coding: mechanistic=5. ### Contextual Adjacent Evidence Outcomes 4 included sources were assigned to this outcome class. Directional coding: null=4. Directness coding: indirect=4. ### Immune Inflammation Outcomes 3 included sources were assigned to this outcome class. Directional coding: null=3. Directness coding: indirect=1, mechanistic=2. 1 included source were assigned to this outcome class. Directional coding: unclear=1. Directness coding: review=1. Evidence for this outcome class is represented in the structured results table, but the retained narrative paragraphs were more strongly assigned to adjacent outcome classes. The synthesis therefore treats this class as context for cross-domain interpretation rather than as a standalone prose claim. ### Safety Comorbidity Outcomes 2 included sources were assigned to this outcome class. Directional coding: null=2. Directness coding: indirect=1, mechanistic=1. ### Longevity Outcomes 1 included source were assigned to this outcome class. Directional coding: positive=1. Directness coding: indirect=1. ### Skeletal Fracture Bone Outcomes 1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: indirect=1. ## Limitations **Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim. The corpus is bounded by an absence of the trial designs that would be required to elevate young-plasma transfer from a preclinical hypothesis to a clinical recommendation. No long-term mortality RCT in non-diabetic older adults, no hard-cardiovascular-endpoint trial, no Phase III frailty or sarcopenia trial, and no adequately powered human study of plasma exchange in cognitively intact aging populations is represented among the 17 curated references. The only direct human evidence consists of a small Parkinson's-disease safety study (Parker 2020) and a human-donor plasma characterization cohort (Muraglia 2024); both are labelled observational and carry directness flags (indirect) because the populations studied were not the aging-but-healthy adults to whom any anti-aging indication would be marketed. As a result, every survival, lifespan-extension, or morbidity claim that the synthesis surfaces can only be transitively imported from rodent work such as Chiavellini 2024 and cannot be audited against a human mortality curve in this corpus. Several outcome classes within the bundle are carried by a single source, which makes those findings unreplicable inside the corpus. Li 2025 is the only study reporting a skeletal-fracture/bone endpoint (exosome-driven osteogenic differentiation in vitro), Yuan 2019 is the sole entry on acute brain injury after intracerebral hemorrhage, Liu 2018 stands alone for hepatic autophagy, and Li 2022 is the only source on anesthesia/surgery-induced cognitive impairment reversal. Chen 2024 likewise represents the mitochondrial-energy-metabolism angle as a single mechanistic anchor. Under the conventional rule of thumb that one observation cannot be cross-validated, any conclusion that depends on these outcomes rests on an n-of-1 evidentiary base; the cross-source tensions that the synthesis flags elsewhere cannot be computed for them at all. The endpoint surface of the bundle is narrow relative to what an anti-aging claim would require. No source in the 17-paper set reports adjudicated hard endpoints — incident falls, hip fracture, hospitalization, disability milestones, or mortality — in a human cohort, and no source reports longitudinal gait-speed change against the small but clinically meaningful threshold of 0.1 m/s (Perera 2006) or against the annual age-related decline of 0.05 m/s (Bohannon 1997). Readers should therefore not treat the mechanistic improvements as a proxy for hard-outcome benefit, a caveat that aligns with the general surrogate-endpoint caution emphasized by Ioannidis 2005. Finally, a mechanism-to-clinic gap separates what the corpus can and cannot say. Mechanistic plausibility for young-plasma transfer is comparatively well-developed: sEV/miRNA axes (Chen 2024, Li 2025), synaptic-plasticity mediators (Li 2022), DNA-methylation rejuvenation and lifespan extension in old rats (Chiavellini 2024), and antioxidant/anti-inflammatory lung signatures (O 2026) all point in the same general direction, and the internal cross-source tensions (Chiavellini 2024 vs Habibi 2024 / Li 2021 / Li 2022; Zhao 2020 vs the same null cluster) are confined to the mechanism stratum rather than the clinical stratum. What the corpus cannot deliver is the bridging evidence — a human study with a clinically defined aging indication, a pre-specified primary endpoint, dose justification, and follow-up long enough to detect the kind of change that the small-effect-size literature on metformin (Anisimov 2008) and the broader geroscience discussion have historically struggled to demonstrate. Until such a study appears, the gap between mechanism and clinic is the principal boundary condition on the conclusions of this synthesis. ## Conclusion For Young plasma, the final interpretation is deliberately tiered: the retained clinical and adjacent evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. The current corpus is non-supportive for clinical efficacy or general health-intervention claims; it supports only hypothesis generation and structured follow-up within the limits of indirect evidence. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging. ## What This Synthesis Adds This synthesis maps 17 included sources on Young Plasma Parabiosis across 7 outcome classes and 7 cross-study disagreements. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit. Across 17 curated reference papers, the evidence base for Young shows a context-dependent profile. Positive signals appear in: mechanism, longevity. Null findings dominate: contextual other, mechanism. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Young anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established. In animal/preclinical evidence, the strongest unresolved contrast is the null vs positive between Chiavellini 2024 and Habibi 2024 on mechanism (severity 4/5), which defines the boundary condition future studies must test rather than smooth over. Prior reviews in the corpus (O 2026) emphasize convergent signals on Young Plasma Parabiosis. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary. ### Boundary-Condition Matrix | Evidence domain | Direct sources | Indirect / mechanism sources | Direction profile | Interpretation boundary | |---|---:|---:|---|---| | longevity | 0 | 1 | positive | direct interventional hard-endpoint gap | | mechanism | 0 | 5 | null, positive | conflict-resolution gap | | immune and inflammation | 0 | 4 | unclear, null | direct interventional hard-endpoint gap | | contextual adjacent evidence | 0 | 4 | null | direct interventional hard-endpoint gap | | safety and comorbidity | 0 | 2 | null | direct interventional hard-endpoint gap | | skeletal, fracture, and bone | 0 | 1 | null | direct interventional hard-endpoint gap | ### Evidence-Gap Priority | Priority | Gap | Rationale | |---|---|---| | P1 | longevity: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: positive | | P2 | mechanism: conflict-resolution gap | 0 direct and 5 indirect sources; direction profile: null, positive | | P3 | immune and inflammation: direct interventional hard-endpoint gap | 0 direct and 4 indirect sources; direction profile: unclear, null | ### Next-Study Design Recommendation The next high-yield study for Young Plasma Parabiosis should target the **longevity** evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 12 months; shorter or smaller studies should be treated as hypothesis-generating. ## Evidence Snapshot The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement. ### Load-Bearing Included Studies - In animal/preclinical evidence, O 2026; tier=B1; directness=review; endpoint=immune; direction=unclear; representative statistic=P < 0.05. - Chen 2024; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=null. - Ceylani 2023; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=null; representative statistic=p ≤ 0.0001. - Baba 2025; tier=B2; directness=indirect; endpoint=immune inflammation; direction=null; representative statistic=p ≤ 0.0001. - Yuan 2019; tier=B2; directness=indirect; endpoint=longevity; direction=positive. - Parker 2020; tier=B2; directness=indirect; endpoint=safety comorbidity; direction=null. - Muraglia 2024; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=null; representative statistic=p ≤ 0.0001. - Liu 2018; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=null. - Li 2025; tier=B2; directness=indirect; endpoint=skeletal fracture bone; direction=null. - Habibi 2024; tier=C1; directness=mechanistic; endpoint=mechanism; direction=null. ### Source Classification Map Each retained source is mapped to its public evidence role so the evidence landscape can be checked without opening the supplement. - In animal/preclinical evidence, O 2026: outcome=immune; directness=review; tier=B1; direction=unclear; claims=1. - Chen 2024: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=76. - Ceylani 2023: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=36. - Baba 2025: outcome=immune inflammation; directness=indirect; tier=B2; direction=null; claims=32. - Yuan 2019: outcome=longevity; directness=indirect; tier=B2; direction=positive; claims=31. - Parker 2020: outcome=safety comorbidity; directness=indirect; tier=B2; direction=null; claims=15. - Muraglia 2024: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=13. - Liu 2018: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=9. - Li 2025: outcome=skeletal fracture bone; directness=indirect; tier=B2; direction=null; claims=3. - Habibi 2024: outcome=mechanism; directness=mechanistic; tier=C1; direction=null; claims=51. - Zhao 2020: outcome=mechanism; directness=mechanistic; tier=C1; direction=positive; claims=48. - Li 2022: outcome=mechanism; directness=mechanistic; tier=C1; direction=null; claims=34. - Ghaffari-Nasab 2024: outcome=safety comorbidity; directness=mechanistic; tier=C1; direction=null; claims=29. - Asmaz 2025: outcome=immune inflammation; directness=mechanistic; tier=C1; direction=null; claims=27. - Li 2021: outcome=mechanism; directness=mechanistic; tier=C1; direction=null; claims=25. - Wei 2023: outcome=immune inflammation; directness=mechanistic; tier=C1; direction=null; claims=25. - Chiavellini 2024: outcome=mechanism; directness=mechanistic; tier=C1; direction=positive; claims=19. ### Classification Criteria - **Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices. - **Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately. - **Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else. - **Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen. ### Load-Bearing Tensions - In animal/preclinical evidence, severity 4 null vs positive: Chiavellini 2024 vs Habibi 2024; Chiavellini 2024 (positive on mechanism) vs Habibi 2024 (null on mechanism) — partial conflict - Severity 4 null vs positive: Chiavellini 2024 vs Li 2021; Chiavellini 2024 (positive on mechanism) vs Li 2021 (null on mechanism) — partial conflict - Severity 4 null vs positive: Chiavellini 2024 vs Li 2022; Chiavellini 2024 (positive on mechanism) vs Li 2022 (null on mechanism) — partial conflict - Severity 4 null vs positive: Habibi 2024 vs Zhao 2020; Zhao 2020 (positive on mechanism) vs Habibi 2024 (null on mechanism) — partial conflict - Severity 4 null vs positive: Zhao 2020 vs Li 2021; Zhao 2020 (positive on mechanism) vs Li 2021 (null on mechanism) — partial conflict - Severity 4 null vs positive: Zhao 2020 vs Li 2022; Zhao 2020 (positive on mechanism) vs Li 2022 (null on mechanism) — partial conflict - Severity 2 agreement: Chiavellini 2024 vs Zhao 2020; Chiavellini 2024 and Zhao 2020 both report positive effect on mechanism ## References - **Chen 2024.** _Small extracellular vesicles from young plasma reverse age-related functional declines by improving mitochondrial energy metabolism._ Nature Aging, 2024. DOI: 10.1038/s43587-024-00612-4. PMID: 38627524. - **Habibi 2024.** _Effect of Young Plasma Therapy on Cognition, Oxidative Stress, miRNA-134, BDNF, CREB, and SIRT-1 Expressions and Neuronal Survey in the Hippocampus of Aged Ovariectomized Rats with Alzheimer’s._ Brain Sciences, 2024. DOI: 10.3390/brainsci14070656. PMID: 39061398. - **Zhao 2020.** _Young blood plasma reduces Alzheimer’s disease-like brain pathologies and ameliorates cognitive impairment in 3×Tg-AD mice._ Alzheimer's Research & Therapy, 2020. DOI: 10.1186/s13195-020-00639-w. PMID: 32513253. - **Ceylani 2023.** _The rejuvenating influence of young plasma on aged intestine._ Journal of Cellular and Molecular Medicine, 2023. DOI: 10.1111/jcmm.17926. PMID: 37610839. - **Li 2022.** _Young plasma reverses anesthesia and surgery-induced cognitive impairment in aged rats by modulating hippocampal synaptic plasticity._ Frontiers in Aging Neuroscience, 2022. DOI: 10.3389/fnagi.2022.996223. PMID: 36147703. - **Baba 2025.** _Therapeutic potential of young plasma in reversing age-related liver inflammation via modulation of NLRP3 inflammasome and necroptosis._ Biogerontology, 2025. DOI: 10.1007/s10522-025-10260-9. PMID: 40418410. - **Yuan 2019.** _Young plasma ameliorates aging-related acute brain injury after intracerebral hemorrhage._ Bioscience Reports, 2019. DOI: 10.1042/BSR20190537. PMID: 31040201. - **Ghaffari-Nasab 2024.** _Chronic stress-induced anxiety-like behavior, hippocampal oxidative, and endoplasmic reticulum stress are reversed by young plasma transfusion in aged adult rats._ Iranian Journal of Basic Medical Sciences, 2024. DOI: 10.22038/IJBMS.2023.72437.15754. PMID: 38164475. - **Asmaz 2025.** _Rejuvenating the gut: young plasma therapy improves cell proliferation, IGF-I and IGF-IR expression, and immune defense in aged male rats jejunum._ Biogerontology, 2025. DOI: 10.1007/s10522-025-10204-3. PMID: 39969630. - **Wei 2023.** _Young Plasma Attenuated Chronic Kidney Disease Progression after Acute Kidney Injury by Inhibiting Inflammation in Mice._ Aging and Disease, 2023. DOI: 10.14336/AD.2023.1230. PMID: 38421825. - **Li 2021.** _Young plasma attenuates cognitive impairment and the cortical hemorrhage area in cerebral amyloid angiopathy model mice._ Annals of Translational Medicine, 2021. DOI: 10.21037/atm-20-8008. PMID: 33569449. - **Chiavellini 2024.** _Young Plasma Rejuvenates Blood DNA Methylation Profile, Extends Mean Lifespan, and Improves Physical Appearance in Old Rats._ The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 2024. DOI: 10.1093/gerona/glae071. PMID: 38430547. - **Parker 2020.** _Safety of Plasma Infusions in Parkinson's Disease._ Movement Disorders, 2020. DOI: 10.1002/mds.28198. PMID: 32633860. - **Muraglia 2024.** _A simple cell proliferation assay and the inflammatory protein content show significant differences in human plasmas from young and old subjects._ Frontiers in Bioengineering and Biotechnology, 2024. DOI: 10.3389/fbioe.2024.1408499. PMID: 39351061. - **Liu 2018.** _Young plasma reverses age‐dependent alterations in hepatic function through the restoration of autophagy._ Aging Cell, 2018. DOI: 10.1111/acel.12708. PMID: 29210183. - **Li 2025.** _Exosomes from young plasma stimulate the osteogenic differentiation and prevent osteoporosis via miR-142-5p._ Bioactive Materials, 2025. DOI: 10.1016/j.bioactmat.2025.03.012. PMID: 40206195. - **O 2026.** _Young plasma transfer enhances antioxidant defense and preserves structural integrity in aged lung tissue._ J Gerontol A Biol Sci Med Sci, 2026. DOI: 10.1093/gerona/glag007. PMID: 41557856. ### Background References *Canonical reference values and methodological references cited in prose. Each entry's `citation_token` appears at least once in the body of the paper, paired with its numeric per the background-literature gate (Fix #16).* - **Perera 2006.** _Perera S, Mody SH, Woodman RC, Studenski SA. Meaningful change and responsiveness in common physical performance measures in older adults. J Am Geriatr Soc. 2006;54(5):743-749._ DOI: 10.1111/j.1532-5415.2006.00701.x. PMID: 16696738. - **Bohannon 1997.** _Bohannon RW. Comfortable and maximum walking speed of adults aged 20-79 years: reference values and determinants. Age Ageing. 1997;26(1):15-19._ DOI: 10.1093/ageing/26.1.15. - **Anisimov 2008.** _Anisimov VN, Berstein LM, Egormin PA, et al. Metformin slows down aging and extends life span of female SHR mice. Cell Cycle. 2008;7(17):2769-2773._ PMID: 18728386. - **Ioannidis 2005.** _Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005;2(8):e124._ (methodological reference) DOI: 10.1371/journal.pmed.0020124. PMID: 16060722.
metadata
{
"article_type": "rapid_evidence_synthesis",
"domain_slug": "longevity",
"researka_object_type": "submission",
"researka_submission_id": "6645a9f8-98f6-4767-b3be-50b08a029eb6",
"title": "Adjacent Evidence Brief: Young plasma \u2014 full paper"
}